跳至主要内容

Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial


 Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials.  IBR854 Injection is a universal off-the-shelf CAR-raNK cell product derived from allogeneic peripheral blood.  The indication is the treatment of patients with unresectable locally advanced or metastatic solid tumors who currently have no or cannot tolerate standard treatment. It is the first non-gene-modified CAR-raNK cell therapy for solid tumors in China, and the world's first FIC (First in class) products.

Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations.  The IBR854 Cell Injection is successfully approved at the end.

Medicilon cell immunotherapy drug service platform
Enabling the sustainable development of global cellular immunotherapy

Cellular immunotherapy is currently known as the most promising treatment for cancer.  In recent years, China's cell therapy industry is booming, and the advent of innovative drugs represented by CAR-T cell therapy has endowed immune cell therapy with more potential.

Medicilon, as a one-stop biopharmaceutical preclinical comprehensive R&D service CRO in China, has always been at the forefront of advanced technology, and has built a one-stop research platform for the preclinical R&D of cellular immunotherapy drugs.  Using a wealth of animal models and a variety of advanced analytical techniques, Medicilon could provide pharmacodynamic research, drug safety evaluation, and pharmacokinetic research for a variety of immunotherapeutic drugs including CAR-T, TCR-T, and CAR-NK, bioanalysis and other R&D services.  Medicilon has completed several preclinical development projects of immunotherapy programs for clients worldwide.

The clinical approval of IBR854 injection means that China's NK cell therapy industry has taken a further step forward, which strongly proves the advantages and innovation capabilities of iMBioRay’s CAR-raNK cell technology platform, as well as the R&D service strength of Medicilon’s cell immunotherapy drug platform.  Both parties accumulated valuable experience to develop more cellular immunotherapy drugs in the future.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文